icsm-avoid-tt-bcr

name	icsm-avoid-tt-bcr
description	Advises against testosterone therapy in men with biochemical recurrence after prostate cancer treatment due to very limited data and potential risk of progression. Consider when a patient has a rising PSA after definitive therapy and the clinician evaluates testosterone for hypogonadism, questioning whether TTh is safe in BCR.

Avoid testosterone therapy in biochemical recurrence

STEP 1 — Gather Information

• Confirm biochemical recurrence: rising PSA after definitive local therapy (e.g., PSA >0.2 ng/mL post‑radical prostatectomy or nadir +2 ng/mL post‑radiotherapy).
• Document symptoms suggestive of hypogonadism (low libido, fatigue, decreased erections).
• Measure total testosterone (morning, fasting) on at least two occasions; confirm low T (<12 nmol/L or <350 ng/dL).
• Exclude other causes of low T (acute illness, medication effects).
• Assess PSA trend and velocity; ensure no evidence of metastatic disease (imaging if clinically indicated).
• Review baseline hematocrit, cardiovascular risk factors, and prostate health (DRE if appropriate).

STEP 2 — Rule In / Rule Out

Rule in if:

• Rising PSA consistent with biochemical recurrence after definitive treatment.
• Symptomatic hypogonadism with confirmed low total testosterone.
  Rule out if:
• Evidence of metastatic prostate cancer or locally advanced disease.
• Active prostate cancer requiring androgen deprivation.
• Contraindications to testosterone (e.g., hematocrit >54%, uncontrolled heart failure, severe sleep apnea).
• PSA elevation due to benign prostatic hyperplasia or infection without true BCR.

STEP 3 — Classify or Stratify

If biochemical recurrence and symptomatic hypogonadism with low T are present, classify as Testosterone therapy contraindicated due to very limited data and potential risk of progression (ICSM Table 6: BCR → Donottreat, LoE 4).

STEP 4 — Decide

• Do not initiate testosterone therapy.
• Address hypogonadism symptoms with lifestyle measures (weight loss, exercise, treat comorbidities).
• Consider enrollment in a clinical trial if appropriate and patient desires investigational therapy.
• Continue PSA monitoring per standard BCR surveillance schedule.

Clinical Guardrails / Mimics / Pitfalls

• Guardrail: Very limited data on testosterone safety in BCR; avoid TTh unless within a trial with rigorous PSA monitoring.
• Mimic: Fatigue or low libido from anemia, depression, or chronic disease may be mistaken for hypogonadism.
• Pitfall: Assuming safety based on lack of increased PCa incidence in hypogonadal men; BCR data are sparse and progression risk unknown.
• Do not prescribe TTh solely to improve quality of life without first excluding progression risk.

Concrete Clinical Example

A 68‑year‑old man status post radical prostatectomy (pathologic T2N0M0) had an undetectable PSA (<0.02 ng/mL) that rose to 0.4 ng/mL over 6 months. He reports decreased libido and fatigue; morning total testosterone is 8 nmol/L on two checks. He asks about starting testosterone gel. According to ICSM guidance, testosterone therapy is contraindicated due to biochemical recurrence and very limited data. He is advised against TRT, evaluated for other causes of symptoms, and placed on standard PSA surveillance every 3 months.

Source: International Consultation on Sexual Medicine (ICSM) 2024, Table 6, Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), 2025, DOI: 10.1093/sxmrev/qeaf036